Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma

At present, concurrent chemoradiotherapy (cCRT) with platin-based dual-drug regimen is the standard treatment for inoperable, locally advanced esophageal cancer in patients with a good performance status. However, cCRT has substantial toxic effects, and a large number of patients with older age, malnutrition and other morbidities, cannot tolerate cCRT. Several phase II trials showed combining PD-1 inhibitor with definitive cCRT provided encouraging activity and acceptable toxicity in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC). Therefore, this single-arm, multi

Trial Details

NCT ID
NCT06342167
Phase
PHASE2
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Radiotherapy
  • Programmed Cell Death Protein 1 Inhibitor
  • Immunonutrition support
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Fujian, Fujian, China
  • Handan, Hebei, China|36.60999,114.48764
  • Anyang, Henan, China|36.096,114.38278
  • Xinxiang, Henan, China|35.19033,113.80151

Key Eligibility Criteria

  • Aged 18 years or order.
  • Diagnosed with locally advanced or early stage esophageal squamous cell carcinoma by pathological examinations of the primary lesion and imaging ex…
  • Confirmed to be unresectable and unable to tolerate synchronous chemoradiotherapy by multidisciplinary consultation, and has not undergone systemic…
  • PD-L1 tumor proportion score or combined positive score of ≥1%.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →